Kazia Therapeutics Says Two Paxalisib Abstracts Accepted for 2026 Symposium Posters
The abstracts cover paxalisib tumor and immune reprogramming research and were accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium.
Related stories
Oracle Shares Fall After Announcing Stock and Bond Transactions
Oracle announced stock transactions and bond transactions; its shares fell.
L impact | EQUITY | Nov 02, 2026, 01:56 PM UTC
Check Point Software Sees Q4 Revenue of $720M-$770M
M impact | EQUITY | Nov 02, 2026, 01:48 PM UTC
Cyberattack on Refrigeration Systems Hits European Supermarkets
A cyberattack on refrigeration systems affected supermarkets across Europe.
M impact | EQUITY | Nov 02, 2026, 01:48 PM UTC
Fox Reports Higher Q1 FY27 EPS and Revenue
Fox reported year-over-year increases in Q1 FY27 earnings per share and revenue.
M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC
IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million
An IDEXX executive said Covet revenue is growing at strong double-digit rates.
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Infineon and Qualcomm Technologies Sign Automated Driving Agreement
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC